Navigation Links
Gene Therapy Shows Promise for Muscular Dystrophy

Small study found technique restored some muscle function for months

FRIDAY, May 21 (HealthDay News) -- Scientists have succeeded in using gene therapy to restore some muscle function in patients with a certain type of muscular dystrophy.

This is the first time such a feat has been performed in humans, state the authors, who are presenting their findings at the annual meeting of the American Society of Gene & Cell Therapy in Washington, D.C.

"This study provides additional information regarding the feasibility of gene therapy for the treatment of muscular dystrophy," said Dr. Valerie Cwik, executive vice president and research and medical director of the Muscular Dystrophy Association, which helped fund the research. "Specifically, it provides proof of principle, in people, for sustained gene expression [for at least six months] following treatment."

"This study has shown that a normal gene packed into a virus and injected directly into a muscle can actually produce the protein that is either defective or missing in this particular form of muscular dystrophy," added Dr. Rabi Tawil, a professor of neurology at the University of Rochester Medical Center. "Similar studies have been done in animal models, and this is the first to show a similar result in humans."

If replicated, the findings could provide hope for people with this and other forms of muscular dystrophy.

"Reversing or significantly blunting the severity of this weakness and wasting will give these patients major improvement in their quality of life, enhance their independence, and increase the likelihood that they can obtain employment," said Dr. Richard Moxley, director of the Neuromuscular Disease Center, also at the University of Rochester Medical Center.

The patients in this study had limb-girdle muscular dystrophy (LGMD), which is characterized by muscle weakness around the hips and shoulders. The condition results from an inherited deficiency of alpha-sarcoglycan, a muscle protein.

"There is no effective therapy to prevent the progressive weakness and loss of muscle that occurs in LGMD type 2D," Moxley explained. "The disease typically begins between 2 and 15 years of age, and many patients become wheelchair-bound by their teens. They have marked weakness of their shoulder and thigh muscles, and have difficulty performing many of the activities of daily life."

"Treatments are needed urgently," stated Cwik.

A previous study of the same gene transfer procedure had been successful in three patients with levels of the protein staying elevated for at least three months after treatment.

Here, a prominent group of muscular dystrophy researchers from the Center for Gene Therapy at the Research Institute at Nationwide Children's Hospital in Columbus, Ohio, injected three LGMD patients with a healthy gene, which succeeded in increasing both gene expression and muscle fiber levels. The effect persisted for six months, the longest yet.

Next, the researchers hope to inject the gene directly into a leg artery to see if those muscles will take up and use the protein.

But several obstacles remain.

"For gene therapy to be clinically beneficial -- meaning an improvement in strength -- multiple muscle groups will need to be treated simultaneously," Cwik said. "To do this will require regional [to an entire limb] or systemic delivery [to the entire body, such as intravenously]."

"This technique delivers the gene directly into the muscle through a needle. It is not practical to do this on large muscles, let alone several muscles, as it would require hundreds of injections," Tawil added. "To make this treatment viable, a system has to be devised where the virus-plus-normal gene can be injected into the circulation and have it deposited into all the muscles. The other obstacle is making sure that injecting the virus containing the normal gene does not induce the immune system to attack the virus."

Also, Cwik said, "we do not know if sustained gene expression will continue for much longer periods of time."

More information

The Muscular Dystrophy Association has more on this condition.

SOURCES: Valerie Cwik, M.D., executive vice president, research, and medical director, Muscular Dystrophy Association, Tucson, Ariz.; Rabi Tawil, M.D., professor, neurology, University of Rochester Medical Center, Rochester, N.Y.; Richard Moxley, M.D., director, Neuromuscular Disease Center, University of Rochester Medical Center, Rochester, N.Y.; May 21, 2010, presentation, American Society of Gene & Cell Therapy, Washington, D.C.

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Targeted therapy prolongs life in patients with HER2-positive breast cancer
2. PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management
3. More smokers kick the habit with extended nicotine patch therapy, Penn research shows
4. Experts Issue Warning on Prostate Hormone Therapy
5. ASGCT: Gene Therapy Shows Promise for Patients with Pompe Disease
6. AAPM statement on quality radiation therapy
7. Congress Urged to Take Immediate Action to Ensure Frail Patients Continue to Receive Critical Therapy Services
8. Intensive Insulin Therapy Wont Boost Septic Shock Survival
9. News brief: Dermatologic infections in cancer patients treated with EGFRI therapy
10. A new target for lymphoma therapy
11. NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is ... a number even greater among Millennials (a whopping one in three aged 18 to ... people who are dissatisfied with their ink. In fact, RealSelf , the world’s ...
(Date:12/1/2015)... ... 01, 2015 , ... For many X-rays taken at hospitals, ... interpretation by the radiologist. The marking utensils are so small, however, they are ... a way to alleviate this problem. , He developed the patent-pending MARK N ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Calif. , Dec. 1, 2015 ... products and services, announced today that it has been ... services organization. Members served by Novation will have access ... devices, sports bracing products and soft goods dedicated to ... --> The aging U.S. population, rising prevalence ...
(Date:12/1/2015)... 2015 Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country of ... registered in Europe in 2015 were tested in ... Russia has always been a country of choice for ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: